Phase 1, Safety and Tolerability Study of XmAb541 and XmAb808 in Advanced Solid Tumors

Part of paid clinical trials in Detroit, Michigan.

Sponsor
Xencor, Inc.
Study ID
NCT07593092
Phase
PHASE1
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex
FEMALE
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • XmAb541 — BIOLOGICAL
    Monoclonal Bispecific Antibody
  • XmAb808 — BIOLOGICAL
    Monoclonal Bispecific Antibody

Study Details

The primary purpose of this study is to determine whether the investigational drug XmAb541 in combination with XmAb808 is safe and well tolerated, and to determine an optimal and safe dose(s) for further study. The study will also evaluate the effect of XmAb541 in combination with XmAb808 on tumor outcomes.

Key Dates

Start date
Jun 30, 2026
Status verified
May 2026
Primary completion
Dec 31, 2028
Completion
Dec 31, 2028

Study Design

Enrollment
90 participants (estimated)
Allocation
NA
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT

Arms

  • Experimental: Dose Escalation and Dose Expansion of XmAb541 and XmAb808

Primary Outcome Measure

Incidence of Adverse Events [ Time Frame: Day 1 to 2 years ]

Central Contacts

Locations (9)

FacilityCityStateZIPSite coordinators
Xencor Investigative SiteDetroitMichigan48201-
Xencor Investigative SiteOmahaNebraska68198-
Xencor Investigative SiteLake SuccessNew York11042-
Xencor Investigative SiteNew YorkNew York10029-
Xencor Investigative SiteThe BronxNew York10461-
Xencor Investigative SiteColumbusOhio43210-
Xencor Investigative SiteOklahoma CityOklahoma73104-
Xencor Investigative SiteFort WorthTexas76104-
Xencor Investigative SiteHoustonTexas77030-

Find similar trials in Detroit, MI

By condition

Related Studies